A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label, dose escalation and dose expansion study of MDK-703 as a monotherapy
and in combination with other cancer therapies in adult study participants with advanced or
metastatic solid tumors.